Beijing Hotgen Biotechn Co., Ltd. (abbreviated as Hotgen Biotech, stock code: 688068) was established in June 2005, which is a high-tech enterprise focusing on the research& development, manufacture and sales of medical and public safety inspection products of in vitro diagnostics (IVD) in the field of biomedicine, as well as landed on the China Sci-Tech innovation board (STAR Market) in September 2019.
After serval years of Research& development, Hotgen Biotech has developed an in vitro diagnostic reagent bioactive raw material development platform, a sugar chain abnormal protein detection (sugar capture) R&D technology platform, a Magnetic particles chemiluminescence R&D technology platform, a Up-converting Phosphor R&D technology platform, and a colloidal gold immune layer, The eight major technology platforms, such as the precipitation R&D platform, enzyme-linked immunoassay R&D technology platform, molecular diagnostics R&D platform, and instrument R&D technology platform, form a closed-loop system for in vitro diagnostic R&D and production. Hotgen Biotech has established a complete full level immunodiagnostic technology platform, from high-precision Up-converting Phosphor POCT (UPT series) to small, medium and large single- cartridge chemiluminescence platforms (MQ60 series), and then to large-scale full-automatic chemiluminescence Platform (C2000), which realizes the application of the immune diagnostic platform in the field of full diagnostic scenarios. Supporting products are widely used in the clinical and public safety fields. Specific users include hospitals at all levels, township health centers, third-party testing centers, and medical institutions, as well as medical and health institutions, as well as disease control centers, public security, fire protection, military, ports, food and medicine. Supervision, food and feed enterprises and other public safety fields.
Hotgen Biotech has won the second prize of the National Technology Invention Award, the Gold Medal of Independent Innovation, and the second prize of the Chinese Medical Science and Technology Award; In 2018, Hotgen Biotech was awarded the second prize of the “Technical Invention Category of China Rare Earth Science and Technology Award” by the China Rare Earth Society; Top 100 Private Scientific and Technological Innovations “and” Top 100 Medical Enterprises of the Future “; and” Postdoctoral Scientific Research Workstation “; major science and technology projects in the 12th and 13th five years, 863 plan, science and technology projects of the Beijing Science and Technology Commission, and Zhongguancun High Precision The project’s major cutting-edge original technological achievements transformation and industrialization projects.
Since its establishment, the company has continuously grown its business and has now achieved group development. At present, Hotgen (Langfang), Hotgen (Jilin), Weikekang Technology, Shunjing Biological and many other subsidiaries have been established. Hotgen Biotech marketing and service network has covered all regions of the country. Each province is equipped with professional technical service engineers, academic engineers, etc. who are responsible for pre-sales and after-sales work to meet customer needs. The company takes “developing biotechnology and benefiting human health” as its mission, “quality determines the company’s life and death, customers determine the company’s success or failure, talents determine the company’s rise and fall, innovation determines the company’s future” as its core values, and “tests because of me advanced” as its philosophy , High ambitions, technological entrepreneurship, and industrial prosperity!
Lepu Medical Technology ( Beijing ) Co., Ltd was established in 1999. It is specialized in developing, manufacturing and marketing high-tech medical devices and equipment.
Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics and general surgery with products include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, electrophysiology catheters, pacemakers, in vitro diagnostic equipment and biomarkers, DSA systems and surgical staplers. In 2009 Lepu Medical successfully went public, and listed on Chinext Shenzhen StockExchange Market ( stock code: 300003).
Vision
To build Lepu Medical into a large-scale global company in the cardiovascular industry that provides products and solutions covering prevention, treatment and rehabilitation for the patients with cardiovascular and related diseases.
To develop Lepu Medical into one of the largest supplier of cardiovascular related products and services on the platforms of medical device, medicine, healthcare products, healthcare service and new medical mode.
To set up a comprehensive online and offline service platform for cardiovascular health, and provide Chinese people with omnipresent care all the while.
In 1990, with the technology and resource advantages of 302 Hospital of the P.L.A., Beijing Kewei Clinical Diagnostic Reagents Manufacturer was established and became one of the earliest companies specialized in producing diagnostic reagents. 302 Hospital of P.L.A. is one of the largest domestic infectious hospitals with many famous clinical and diagnostic experts. It injected its advanced technology and invaluable knowledge asset into Kewei Clinical Diagnostic Reagents Manufacturer. In late 2003, by enterprise reform and assets’ recombination, the former Kewei Clinical Diagnostic Reagents Manufacturer became a modern enterprise characterized by advanced management and market system-Beijing Kewei Clinical Diagnostic Reagents Co., Ltd, and with 302 Hospital set up the Cooperation Center of Research and Development for Clinical Diagnostic Reagents. At present, Kewei has obtained GMP certificate and has a 3000 square meter clean room meeting GMP requirements that laid the reliable foundation for good product quality.
Kewei’s products include the diagnostic kits of hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B ‘e’ antigen, hepatitis B ‘e’ antibody and hepatitis B core antibody, hepatitis a virus IgM diagnostic kits, hepatitis E virus IgM diagnostic kits, RPR diagnostic kits, HBV test cassettes, HIV Ag/Ab diagnostic kits, etc. And the research and application of monoclonal antibodies against various hepatitis viruses was awarded the second prize issued by the Ministry of Science and Technology (MOST) P. R. China. Then Kewei became the first one obtained the Certificate of New Drug of EIA kit for HAV IgM and for anti-HBc. In November 2004, Kewei was awarded a certificate of high and new technological enterprise by Beijng Science and Technology Commission. In November 2005, the international forth generation HIV Ab/Ag diagnostic kit was supported by innovation fund of the year 2005 under Ministry of Science and Technology.
Kewei have a professional and experienced sales team. The Domestic and International market sales volume increases rapidly each year, is the superior positions in blood screening tests for infectious diseases in China. Our marketing efforts extend to the fields of clinical testing, disease control and prevention, blood screening etc.
JWF maintains long-term technical collaborations with various scientific research institutions of China including Academy of Military Medical Sciences and Chinese Academy of Sciences and has invited many experts and professors in bio-pharmaceutical sector as technical consultant of the company. At the present, Beijing JWF plans to build the Detection Platform of Food Safety with AQSIQ, the Ministry of Agriculture, the Academy of Military Medical Sciences and Shanghai Jiaotong University with the intent of offering escort to the public health. Meanwhile, Beijing JWF has cooperated with Academy of Military Medical Sciences in the anti-terrorism project of rapid detection of virus.
Through independent research and development, the company now focus on the IVD Reagents development and has created 4 series of product lines with proprietary intellectual property rights:
★ The development of monoclonal antibody and recombinant antigen.
★ Rapid colloid-gold labeled / latex labeled immunological diagnosis kits : infectious disease detection; prenatal detection; tumor marker detection; cardiac marker detection; microbiological analysis; hormone test; specific proteins test; biochemical index test; zoonosis detection…
Among these, JWF P.f/P.v plasmodium detection kit is financed by National Innovation Fund and has applied for patent protection.
★ Quantitative Analysis Platform of Chemiluminescent and Fluorescence immunochromatography Assay: This is a rapid quantitative detection technology. Beijing JWF has cooperations with returned scientists studying in the United States. The platform is in compliance with international advanced level. Now we’re applying for the patents and intellectual properties for JWF Quantitative Analysis Platform.
★ Molecular Diagnostic Reagent Kits: JWF uses molecular biology to test the gene structure and the genotype of the subjects. The diseases including genetic disease, infectious disease and tumors are tested and diagnosed based on genes level. After continuous investment and development, JWF has created a professional R&D team with rich experiences and supported by sophisticated and complete R&D facilities to carry out the development of new products and technologies.
Beijing JWF is honored as national high-tech enterprise, Zhongguancun high-tech enterprise and is also a member of Zhongguancun Credit Promotion Association, member of Development Funds for International Market Expansion of Middle and Small-sized Enterprises, member of Z-park Nutrition and Health Promotion Industrial Technology Alliance. In 2011, JWF was awarded as Pilot Unit of Intellectual Property of Beijing. The company has participated in the development and implementation of the nation´s 863 Program and Major National Project for many times. Many products of the company have received support from Zhongguancun and National Innovation Fund.
Since the inception in November 2013, Biohit Healthcare (Hefei) Co., Ltd. has been committed to the R&D and application of in vitro diagnostic (IVD) devices and supporting instruments. We have obtained ISO 13485 Quality Management System certification and the Medical Device Production License. We have also been evaluated as National High-tech Enterprise.
Through independent innovation, our IVD technology for digestive diseases, represented by the serum gastric function test, has reached an international advanced level. In December 2018, the serum gastric function test was introduced in the Chinese Guidelines for Diagnosis and Treatment of Cancer by the Health Care Commission as the only method for gastric cancer screening, and the relevant diagnosis standards are also based on the company’s products. Currently, our products have received 20 medical device certificates, among which the chemiluminescence and fluorescence immunochromatography kits for Gastrin-17 are both the first-in-class.
Since the outbreak of COVID-19 in early 2020, Biohit (Hefei) has proactively participated in combating the pandemic. Based on previous technology development in the IVD industry, we have developed a number of COVID-19 antigen and antibody tests. The antibody test has been granted EUA by the US-FDA and the antigen blood test is the first of its kind in the world. We also developed rapid 15-min easy-to-use antigen tests based on Colloidal Gold method and Fluorescence Immunochromatography. The Fluorescence test can deliver higher sensitivity when used with supporting analyzer. So far, our tests have been distributed to more than 50 countries and regions.
Anhui Deep Blue Medical Technology Co., Ltd. was established in February 4, 2010 and located in Hefei High-tech Zone, Anhui, China. Deep Blue Medical is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of diagnostic reagents and biological raw materials.
Deep Blue Medical have advanced rapid diagnostic reagent production lines and the latest clinical testing technologies. The products have many advantages such as simple operation, accurate and reliable, timely and convenient and so on. its technical performance has been to the domestic advanced level. Deep Blue Medical has already passed the assessment of the Quality Supervision Bureau of the Food and Drug Administration, established the YY / T 0287-2017 ISO13485:2016 quality management system.
Our main products are HCG Pregnancy Test Strips, LH Ovulation Test Strips, Fecal Occult Blood Test series, IGFBP-1 PROM Test Kits, Bacterial Vaginosis Test series, PCT Test Kits and Medical Ultrasonic Couplant and so on, cover three categories of gynecological maternity, family planning and digestive medicine. Customers’ designs (OEM / ODM) are also welcome. We’ve been and will keep on aiming at providing high quality products and excellent after-sales services to both domestic and overseas customers. We are looking forward to establishing relationships with you in the near future.
Established in Feb.2019, Anhui Formaster Biosci Co., Ltd. is located in Anhui Wuwei Economic Development Zone. The site area is 1,500 sq. meters with a clean room of 300 sq. meters. The company is specialized in researching, developing and manufacturing in vitro diagnostic (IVD) devices with advanced technology, high R&D input and innovation. Granted CE certification, the leading products are rapid diagnostic devices, focusing on the following 7 categories, COVID-19 antibody, women’s health, infectious diseases, drugs, cancer, cardiovascular and respiratory. Our professional team is the national leader in colloidal gold, latex and other labelling technologies, biological raw materials technologies, including monoclonal antibodies, polyclonal antibodies, genetic recombinant antigens, synthetic antigen, etc., as well as other cutting-edge biological fields, such as immunochromatography.
Genrui Biotech Inc. (formerly known as “Shenzhen Genius Electronics Co., Ltd”), is one of the leading Chinese companies specialized in developing, manufacturing and marketing IVD equipment and reagents. Established in 2004, Genrui has experienced great progress in both product development and market presence. Product range covers Immunoassay, Chemistry, Hematology, Urinalysis, and Point-of-Care, as well as associated reagents, while market presence spreads across whole of China and more than 100 countries worldwide.
Being a national high-tech enterprise and an ISO9001 & ISO13485 qualified company, Genrui has implemented high standards to every aspect from product development, manufacturing, quality control and customer relations. With the core value “Innovation, Quality, Service” rooted in mind, our vision is to become a worldwide reputable brand for IVD.
Medpro (Hefei, China) Healthcare Co., Ltd was established in 2003, which is one of the earliest and most professional manufacturers for medical protective productions, our company located in the science and education city of Hefei and beautiful Huangshan city. We are always committed to reducing hospital infection and improving the occupational protection with the motto of Honesty, Responsibility and Thanksgiving, focusing on the researching ,producing and marketing for the top disposable medical protective productions and medical dressing, as the partner of Fortune 500 Companies, such as DuPont, 3M, Merck, and so on. Medpro’s products are favored by domestic and foreign customers.